Monitor

What just changed and what’s coming. Actual and guided are never confused.

All eventsGuided onlyActual onlyTrial Readout (864)Corporate Filing (685)Label Expansion (60)Guided Milestone (4)Regulatory Action (22)Congress Presentation (19)
250 events
2050-02
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumpt — primary completionest.
Trial Readout · NCT03883360
2032-02-01
Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patien — primary completionest.
Trial Readout · NCT07152184
2031-12
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizoph — primary completionest.
Trial Readout · NCT07114874
2030-04-30
Cognitive Strategies in Early Psychosis 2 — primary completionest.
Trial Readout · NCT07263022
2030-04-30
Cognitive Strategies in Early Psychosis 1 — primary completionest.
Trial Readout · NCT07231497
2030-03-08
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC f — primary completionest.
Trial Readout · NCT07424404
2030-02
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia — primary completionest.
Trial Readout · NCT07459647
2029-12-18
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizo — primary completionest.
Trial Readout · NCT07288567
2029-12-01
Stratification and Treatment in Early Psychosis Study - PROMOTE — primary completionest.
Trial Readout · NCT07434973
2029-12
Sex Differences in NMDA-enhancing Treatment of Schizophrenia — primary completionest.
Trial Readout · NCT07122895
2029-11-30
Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophr — primary completionest.
Trial Readout · NCT07592169
2029-07
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia — primary completionest.
Trial Readout · NCT07227818
2029-06-01
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illn — primary completionest.
Trial Readout · NCT06376734
2029-05-01
No Guts No Glory Probiotics — primary completionest.
Trial Readout · NCT07606014
2029-03
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis — primary completionest.
Trial Readout · NCT07459660
2029-01-01
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairm — primary completionest.
Trial Readout · NCT07084831
2028-12
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia — primary completionest.
Trial Readout · NCT06574360
2028-12
52-week Open Label Safety-Tolerability Study — primary completionest.
Trial Readout · NCT07369154
2028-09-23
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japane — primary completionest.
Trial Readout · NCT06882785
2028-09
Stratification and Treatment in Early Psychosis Study -ASSIST — primary completionest.
Trial Readout · NCT07326124
2028-08-01
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophreni — primary completionest.
Trial Readout · NCT06939088
2028-06-30
Ocrelizumab for Psychosis by Autoimmunity — primary completionest.
Trial Readout · NCT03971487
2028-06-30
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disord — primary completionest.
Trial Readout · NCT05603104
2028-04-30
Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodi — primary completionest.
Trial Readout · NCT06340789
2028-04-01
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Prob — primary completionest.
Trial Readout · NCT04323566
2028-03-31
Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on — primary completionest.
Trial Readout · NCT06881810
2028-03
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia — primary completionest.
Trial Readout · NCT07225712
2028-02-21
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Ps — primary completionest.
Trial Readout · NCT06947941
2028-02
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emrac — primary completionest.
Trial Readout · NCT07145918
2028-02
Stratification and Treatment in Early Psychosis Study - ENHANCE — primary completionest.
Trial Readout · NCT06778564
2028-01
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia — primary completionest.
Trial Readout · NCT03794076
2027-12-31
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophr — primary completionest.
Trial Readout · NCT07045142
2027-12-31
A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psycho — primary completionest.
Trial Readout · NCT07396870
2027-12-31
Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in P — primary completionest.
Trial Readout · NCT07309159
2027-12
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alz — primary completionest.
Trial Readout · NCT06887192
2027-12
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Neg — primary completionest.
Trial Readout · NCT07565428
2027-12
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia — primary completionest.
Trial Readout · NCT06021197
2027-12
A Cognitive Mobile Intervention for Motivation in Psychotic Disorders — primary completionest.
Trial Readout · NCT07674914
2027-12
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizop — primary completionest.
Trial Readout · NCT06229210
2027-12
Enhancing Recovery in Early Schizophrenia — primary completionest.
Trial Readout · NCT02926859
2027-11
A Study of Brenipatide in Adult Participants With Schizophrenia — primary completionest.
Trial Readout · NCT07410507
2027-11
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizoph — primary completionest.
Trial Readout · NCT07105098
2027-11
Randomized Withdrawal Study in Patients With Schizophrenia — primary completionest.
Trial Readout · NCT06961968
2027-10-01
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders — primary completionest.
Trial Readout · NCT05838560
2027-10
A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Recept — primary completionest.
Trial Readout · NCT07626034
2027-10
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizoph — primary completionest.
Trial Readout · NCT06963034
2027-09
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects — primary completionest.
Trial Readout · NCT04987229
2027-09
Monotherapy of an NMDA Enhancer for Schizophrenia — primary completionest.
Trial Readout · NCT04745143
2027-08
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia — primary completionest.
Trial Readout · NCT07288333
2027-07-29
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Ho — primary completionest.
Trial Readout · NCT07467993
2027-06
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizoph — primary completionest.
Trial Readout · NCT07363577
2027-05
A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Sch — primary completionest.
Trial Readout · NCT06821945
2027-04-30
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 — primary completionest.
Trial Readout · NCT03194815
2027-04-30
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia — primary completionest.
Trial Readout · NCT07423546
2027-04-01
D-serine AudRem: R33 Phase — primary completionest.
Trial Readout · NCT05046353
2027-03
Tolerability of MDMA in Schizophrenia — primary completionest.
Trial Readout · NCT05770375
2027-03
Synbiotic Compound to Reduce Symptoms of Schizophrenia — primary completionest.
Trial Readout · NCT04226898
2027-02
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resista — primary completionest.
Trial Readout · NCT05240976
2027-01-31
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunct — primary completionest.
Trial Readout · NCT06191965
2027-01-01
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1) — primary completionest.
Trial Readout · NCT04589208
2027-01
Accelerated TMS in Psychosis — primary completionest.
Trial Readout · NCT05567848
2026-12-31
Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Actin — primary completionest.
Trial Readout · NCT07185815
2026-12-31
A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone — primary completionest.
Trial Readout · NCT06878833
2026-12-31
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subje — primary completionest.
Trial Readout · NCT07184619
2026-12-15
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants ( — primary completionest.
Trial Readout · NCT03817502
2026-12-15
Efficiency of a Composite Personalised Care on Functional Outcome in Early Psych — primary completionest.
Trial Readout · NCT05796401
2026-12-01
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia — primary completionest.
Trial Readout · NCT05778591
2026-12
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. — primary completionest.
Trial Readout · NCT06482554
2026-12
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia — primary completionest.
Trial Readout · NCT04959201
2026-12
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early — primary completionest.
Trial Readout · NCT04411225
2026-11-24
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer — primary completionest.
Trial Readout · NCT06585787
2026-11
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia — primary completionest.
Trial Readout · NCT04917302
2026-11
Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schi — primary completionest.
Trial Readout · NCT06315972
2026-11
A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the T — primary completionest.
Trial Readout · NCT07521683
2026-10-20
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participan — primary completionest.
Trial Readout · NCT06894212
2026-10
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer — primary completionest.
Trial Readout · NCT05052853
2026-10
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With — primary completionest.
Trial Readout · NCT07191483
2026-09-30
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled — primary completionest.
Trial Readout · NCT03094429
2026-09
Treating Schizophrenia by Correcting Abnormal Brain Development — primary completionest.
Trial Readout · NCT00179465
2026-09
An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Thet — primary completionest.
Trial Readout · NCT06351514
2026-09
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric — primary completionest.
Trial Readout · NCT05303064
2026-08-30
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults — primary completionest.
Trial Readout · NCT05622201
2026-08
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inp — primary completionest.
Trial Readout · NCT07038876
2026-07-01
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral — primary completionest.
Trial Readout · NCT06529029
2026-07
Study on the Efficacy and Safety of QLM1016 in Schizophrenia — primary completionest.
Trial Readout · NCT06799559
2026-06-30
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and — primary completionest.
Trial Readout · NCT05064319
2026-06-30
Acetazolamide for Treatment Resistant Schizophrenia — primary completionest.
Trial Readout · NCT04887792
2026-06-08
Metformin Treatment on Cognitive Impairment of Schizophrenia — primary completion
Trial Readout · NCT05838573
2026-06
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in — primary completionest.
Trial Readout · NCT06589817
2026-06
Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olan — primary completionest.
Trial Readout · NCT05669742
2026-04
A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia — primary completionest.
Trial Readout · NCT06649214
2026-03-19
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive Kar — primary completionest.
Trial Readout · NCT05304767
2026-03
Study of SPG302 in Adults With Schizophrenia — primary completionest.
Trial Readout · NCT06442462
2026-02
Study of ALTO-101 in Patients With Schizophrenia — primary completionest.
Trial Readout · NCT06502964
2026-02
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schiz — primary completionest.
Trial Readout · NCT05325645
2026-01-30
Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone — primary completion
Trial Readout · NCT07575516
2026-01-15
Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Di — primary completionest.
Trial Readout · NCT05946486
2026-01-02
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults Wit — primary completion
Trial Readout · NCT07550387
2025-12-31
Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia — primary completionest.
Trial Readout · NCT04761861
2025-11-25
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use — primary completion
Trial Readout · NCT04105231
2025-10-07
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia — primary completion
Trial Readout · NCT07116694
2025-10-06
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerabilit — primary completion
Trial Readout · NCT04578756
2025-08-15
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and — primary completion
Trial Readout · NCT05658510
2025-08
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation i — primary completionest.
Trial Readout · NCT05326347
2025-08
Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia — primary completionest.
Trial Readout · NCT06387771
2025-06-30
A Study of ANAVEX3-71 in Adults With Schizophrenia — primary completionest.
Trial Readout · NCT06245213
2025-06-25
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Pa — primary completion
Trial Readout · NCT05443724
2025-06-20
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Sym — primary completion
Trial Readout · NCT05838625
2025-06-13
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment — primary completion
Trial Readout · NCT06067984
2025-04-22
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance — primary completion
Trial Readout · NCT03238326
2025-04-09
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated W — primary completion
Trial Readout · NCT05686239
2025-04-01
R33: Levetiracetam in Early Psychosis — primary completion
Trial Readout · NCT04317807
2025-03-30
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia — primary completion
Trial Readout · NCT04857983
2025-03-19
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inade — primary completion
Trial Readout · NCT05145413
2025-03-13
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effe — primary completion
Trial Readout · NCT06572449
2025-02-28
Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and In — primary completion
Trial Readout · NCT07477301
2025-02-26
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who — primary completion
Trial Readout · NCT05211947
2025-02-04
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as — primary completion
Trial Readout · NCT05110157
2025-02
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia — primary completionest.
Trial Readout · NCT05184335
2025-01-30
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Dis — primary completionest.
Trial Readout · NCT04529226
2024-12-30
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia — primary completion
Trial Readout · NCT04414930
2024-12-20
Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia — primary completionest.
Trial Readout · NCT04895488
2024-12-04
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB — primary completion
Trial Readout · NCT06179108
2024-12-02
The Sub-Sero Study — primary completion
Trial Readout · NCT03994965
2024-11
Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Sy — primary completionest.
Trial Readout · NCT04518319
2024-10-28
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in Peo — primary completion
Trial Readout · NCT04860830
2024-10-18
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schi — primary completion
Trial Readout · NCT04846881
2024-09-23
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effect — primary completion
Trial Readout · NCT05741528
2024-09-23
A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania — primary completion
Trial Readout · NCT03383874
2024-09-20
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazin — primary completion
Trial Readout · NCT05368558
2024-09-17
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schi — primary completion
Trial Readout · NCT04846868
2024-09-16
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a — primary completion
Trial Readout · NCT02088060
2024-09-16
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospital — primary completion
Trial Readout · NCT05919823
2024-08-23
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schi — primary completion
Trial Readout · NCT05227690
2024-08-21
Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Function — primary completion
Trial Readout · NCT05414058
2024-08-15
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schi — primary completion
Trial Readout · NCT05227703
2024-08-14
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophren — primary completion
Trial Readout · NCT04013555
2024-07-25
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia — primary completion
Trial Readout · NCT04959032
2024-07-10
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults Wi — primary completion
Trial Readout · NCT05545111
2024-06-30
Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patient — primary completionest.
Trial Readout · NCT05964790
2024-06-30
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia — primary completion
Trial Readout · NCT03034356
2024-06-28
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Part — primary completion
Trial Readout · NCT05182476
2024-06-21
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episod — primary completion
Trial Readout · NCT04624243
2024-06-05
Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in P — primary completion
Trial Readout · NCT05278156
2024-06-01
Sodium Nitroprusside in Early Course Schizophrenia — primary completion
Trial Readout · NCT04986072
2024-05-31
Substance Misuse To Psychosis for Stimulants — primary completion
Trial Readout · NCT03485417
2024-05-24
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy o — primary completion
Trial Readout · NCT04820309
2024-05-07
A Study of Olanzapine in Patients With Acute Agitation — primary completionest.
Trial Readout · NCT05803642
2024-04-30
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia — primary completion
Trial Readout · NCT03121586
2024-04-01
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is — primary completion
Trial Readout · NCT05628103
2024-03-26
The Effectiveness and Efficacy of the Combination of the Integrated Psychologica — primary completion
Trial Readout · NCT05623228
2024-03-25
Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia — primary completion
Trial Readout · NCT05643196
2024-03-22
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Parti — primary completion
Trial Readout · NCT04457310
2024-03-21
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 — primary completion
Trial Readout · NCT05359081
2024-03-19
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Te — primary completion
Trial Readout · NCT05693935
2024-03-18
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Predi — primary completion
Trial Readout · NCT05193578
2024-02-23
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients — primary completion
Trial Readout · NCT03943537
2024-01-31
A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Respon — primary completion
Trial Readout · NCT03900754
2024-01-25
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Sym — primary completion
Trial Readout · NCT04531982
2023-12-31
Pharmacological Modulation of Hippocampal Activity in Psychosis 2 — primary completion
Trial Readout · NCT04559529
2023-12-31
Siltuximab in Schizophrenia — primary completionest.
Trial Readout · NCT02796859
2023-11-29
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophre — primary completion
Trial Readout · NCT02261519
2023-11-09
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investi — primary completion
Trial Readout · NCT04109950
2023-11-08
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Ad — primary completion
Trial Readout · NCT05654870
2023-11-03
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acti — primary completion
Trial Readout · NCT05779241
2023-10-26
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen® — primary completion
Trial Readout · NCT01908192
2023-10-12
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Ps — primary completion
Trial Readout · NCT04825860
2023-10-03
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of Kar — primary completion
Trial Readout · NCT04659174
2023-09-27
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatm — primary completion
Trial Readout · NCT03510325
2023-09-06
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatmen — primary completion
Trial Readout · NCT03201757
2023-07-17
Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients W — primary completionest.
Trial Readout · NCT05168007
2023-06-30
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder — primary completion
Trial Readout · NCT02918370
2023-06-14
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational D — primary completion
Trial Readout · NCT04092686
2023-06-12
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People Wi — primary completion
Trial Readout · NCT03437668
2023-05-23
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symp — primary completion
Trial Readout · NCT03896945
2023-05-12
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in — primary completion
Trial Readout · NCT04072354
2023-04-03
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy — primary completion
Trial Readout · NCT03198078
2023-03-12
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Sc — primary completion
Trial Readout · NCT03669640
2023-03-01
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, — primary completion
Trial Readout · NCT05643170
2023-02-10
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to — primary completion
Trial Readout · NCT04418466
2022-12-30
A Study of the Long-term Safety and Tolerability of an Investigational Drug in P — primary completion
Trial Readout · NCT04115319
2022-12-27
A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA — primary completion
Trial Readout · NCT06356389
2022-12
SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizoph — primary completionest.
Trial Readout · NCT04528095
2022-11-29
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized — primary completion
Trial Readout · NCT04738123
2022-10-26
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely — primary completion
Trial Readout · NCT03465787
2022-09-30
This Study Tests Whether BI 425809 Together With Brain Training Using a Computer — primary completion
Trial Readout · NCT03859973
2022-08-31
Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia — primary completionest.
Trial Readout · NCT03497299
2022-08-12
A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients — primary completion
Trial Readout · NCT04521868
2022-07-29
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in — primary completion
Trial Readout · NCT04524403
2022-07-19
Carnosine and Cognitive Training in Schizophrenia — primary completion
Trial Readout · NCT02686697
2022-06-21
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in — primary completion
Trial Readout · NCT04512066
2022-06-17
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CO — primary completion
Trial Readout · NCT03818256
2022-05-24
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized — primary completion
Trial Readout · NCT04659161
2022-05-03
A Study of Paliperidone Palmitate 6-Month Formulation — primary completion
Trial Readout · NCT04072575
2022-04
Pentoxifylline Add-on Therapy for Schizophrenia — primary completionest.
Trial Readout · NCT05073640
2022-03-31
Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019) — primary completion
Trial Readout · NCT03983018
2022-03-23
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cogn — primary completion
Trial Readout · NCT03745820
2022-03-16
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adj — primary completion
Trial Readout · NCT04421456
2022-03-11
Schizophrenia Treatment With Photoneuromodulation — primary completion
Trial Readout · NCT05339347
2022-01-04
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkins — primary completion
Trial Readout · NCT03582137
2021-12-31
L-arginine Study for Persistent Symptoms of Schizophrenia — primary completion
Trial Readout · NCT04054973
2021-12-31
The Norwegian Prednisolone in Early Psychosis Study — primary completion
Trial Readout · NCT03340909
2021-12-02
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia — primary completion
Trial Readout · NCT03893825
2021-12-01
Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia — primary completion
Trial Readout · NCT03788759
2021-12-01
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who H — primary completion
Trial Readout · NCT03187769
2021-11-03
Levetiracetam in Early Psychosis — primary completion
Trial Readout · NCT03129360
2021-10-28
Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia — primary completion
Trial Readout · NCT04822883
2021-09-30
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Sch — primary completion
Trial Readout · NCT04094207
2021-08-06
Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia — primary completion
Trial Readout · NCT03874494
2021-07-01
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder — primary completion
Trial Readout · NCT03043820
2021-04-30
D-serine Augmentation of Neuroplasticity — primary completion
Trial Readout · NCT03711500
2021-03-17
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Men — primary completion
Trial Readout · NCT03230097
2021-03-10
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Bec — primary completion
Trial Readout · NCT03351244
2021-02-20
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patien — primary completion
Trial Readout · NCT04461119
2021-02-11
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine — primary completion
Trial Readout · NCT03593213
2021-01-30
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients — primary completion
Trial Readout · NCT03955549
2021-01
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine — primary completion
Trial Readout · NCT03149107
2020-12-30
Berberine as Adjuvant Treatment for Schizophrenia Patients — primary completion
Trial Readout · NCT02983188
2020-12-30
Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schi — primary completion
Trial Readout · NCT03510741
2020-12-29
A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Sympto — primary completion
Trial Readout · NCT03382639
2020-12-22
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive — primary completion
Trial Readout · NCT04158687
2020-12-22
A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone E — primary completion
Trial Readout · NCT04567524
2020-12-21
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophr — primary completion
Trial Readout · NCT03359785
2020-10-15
Estradiol as add-on to Antipsychotics — primary completionest.
Trial Readout · NCT04093518
2020-10-07
Telmisartan Pilot Study on Treatment Resistant Schizophrenia — primary completion
Trial Readout · NCT03868839
2020-09-30
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Part — primary completion
Trial Readout · NCT03503318
2020-09-23
ITI-007 (Lumateperone Tosylate) for Schizophrenia — primary completion
Trial Readout · NCT03817528
2020-09-01
Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophr — primary completion
Trial Readout · NCT03929497
2020-08-31
Pharmacologic Modulation of Hippocampal Activity in Psychosis — primary completion
Trial Readout · NCT04277936
2020-08-20
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Sc — primary completion
Trial Readout · NCT03793712
2020-08-12
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-mon — primary completion
Trial Readout · NCT03892889
2020-08
NRX-1074 in Early Course Schizophrenia — primary completionest.
Trial Readout · NCT02603458
2020-08
Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Functio — primary completionest.
Trial Readout · NCT03284294
2020-08
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia. — primary completion
Trial Readout · NCT02634684
2020-07-30
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY) — primary completion
Trial Readout · NCT04327843
2020-07-08
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipola — primary completion
Trial Readout · NCT04030143
2020-06-03
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychot — primary completionest.
Trial Readout · NCT03790345
2020-05-26
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patient — primary completion
Trial Readout · NCT03397134
2020-05-08
A Study of Paliperidone Palmitate 6-Month Formulation — primary completion
Trial Readout · NCT03345342
2020-05-06
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia — primary completion
Trial Readout · NCT04268303
2020-05-04
Treating Smokers With Mental Illness — primary completion
Trial Readout · NCT03822416
2020-05-01
A Study of Staccato Loxapine (ADASUVE®) for Inhalation — primary completionest.
Trial Readout · NCT04148963
2020-02
rTMS Treatment for Positive and Negative Symptoms of Schizophrenia — primary completionest.
Trial Readout · NCT03413527
2020-01-30
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression — primary completion
Trial Readout · NCT03044249
2020-01-08
Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With A — primary completion
Trial Readout · NCT03870880
2020-01-01
Add-on Methotrexate for the Treatment of Schizophrenia — primary completionest.
Trial Readout · NCT03369795
2020-01
Treatment of Psychosis and Agitation in Alzheimer's Disease — primary completion
Trial Readout · NCT02129348
2019-12-31
Aspirin in Young Psychotic Patients — primary completion
Trial Readout · NCT02685748
2019-12-31
Tryptophan MRI in People With Schizophrenia and Healthy Controls — primary completion
Trial Readout · NCT02067975
2019-12-27
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schiz — primary completion
Trial Readout · NCT02832037